Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 832.75M | 783.25M | 933.69M | 800.13M | 647.41M | 532.67M |
Gross Profit | 250.72M | 185.56M | 210.84M | 184.83M | 96.57M | 76.08M |
EBITDA | 106.23M | 95.33M | 98.22M | 85.58M | 56.32M | 41.00M |
Net Income | 34.34M | 30.42M | 40.37M | 41.51M | 29.76M | 17.47M |
Balance Sheet | ||||||
Total Assets | 0.00 | 1.17B | 544.55M | 409.87M | 373.15M | 222.94M |
Cash, Cash Equivalents and Short-Term Investments | 438.46M | 438.46M | 13.31M | 15.94M | 8.06M | 11.67M |
Total Debt | 0.00 | 199.03M | 156.23M | 115.78M | 76.85M | 41.48M |
Total Liabilities | -850.25M | 323.98M | 255.92M | 161.46M | 166.31M | 72.05M |
Stockholders Equity | 850.25M | 850.25M | 288.63M | 248.40M | 206.84M | 176.91M |
Cash Flow | ||||||
Free Cash Flow | 0.00 | -150.41M | -31.30M | -24.90M | -37.75M | -7.57M |
Operating Cash Flow | 0.00 | -38.52M | 60.59M | 28.96M | -5.83M | 789.00K |
Investing Cash Flow | 0.00 | -237.26M | -89.09M | -57.33M | -24.80M | -11.71M |
Financing Cash Flow | 0.00 | 575.17M | 26.67M | 30.11M | 31.22M | 12.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | ₹23.52B | 22.75 | ― | 1.28% | 9.42% | -4.36% | |
64 Neutral | ₹22.79B | 55.87 | ― | 0.43% | 6.84% | 19.27% | |
64 Neutral | ― | 46.98 | ― | ― | -4.70% | -18.36% | |
58 Neutral | ₹65.79B | 193.22 | ― | 0.15% | 10.13% | -73.45% | |
58 Neutral | ₹2.81B | 53.32 | ― | ― | 4.84% | 6.90% | |
57 Neutral | ₹7.87B | 32.75 | ― | 0.38% | -2.77% | -50.71% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% |
AVRO India Ltd. has announced the closure of its trading window in compliance with SEBI regulations and the company’s insider trading code. This closure will be in effect from July 1, 2025, until 48 hours after the release of the company’s unaudited financial results for the quarter ending June 30, 2025. The move is aimed at preventing insider trading by restricting designated persons and insiders from dealing in the company’s equity shares during this period.